Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: Impact on stem cell harvesting and engraftment

References

• Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32
   PubMed Web of Science ®Google Scholar
• Gertz M A, Lacy M Q, Dispenzieri A, Hayman S R, Kumar S K. High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myeloma. Expert Rev Anticancer Ther 2006; 6: 343–360
   PubMed Web of Science ®Google Scholar
• Harousseau J L. Stem cell transplantation in multiple myeloma (0, 1, or 2). Curr Opin Oncol 2005; 17: 93–98
   PubMed Web of Science ®Google Scholar
• Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole D H, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793
   PubMed Web of Science ®Google Scholar
• Child J A, Morgan G J, Davies F E, Owen R G, Bell S E, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883
   PubMed Web of Science ®Google Scholar
• Barlogie B, Kyle R A, Anderson K C, Greipp P R, Lazarus H M, Hurd D D, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929–936
   PubMed Web of Science ®Google Scholar
• Bladé J, Rosinol L, Sureda A, Ribera J M, Diaz-Mediavilla J, Garcia-Larana J, et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755–3759
   PubMed Web of Science ®Google Scholar
• Fermand J P, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M, et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227–9233
   PubMed Web of Science ®Google Scholar
• Alvares C L, Davies F E, Horton C, Patel G, Powles R, Sirohi B, et al. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Br J Haematol 2005; 129: 607–614
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and post-transplantation consolidation therapies. Blood 2006; 107: 2633–2638
   PubMed Web of Science ®Google Scholar
• Krejci M, Buchler T, Hajek R, Svobodnik A, Krivanova A, Pour L, et al. Prognostic factors for survival after autologous transplantation: a single centre experience in 133 multiple myeloma patients. Bone Marrow Transplant 2005; 35: 159–164
   PubMed Web of Science ®Google Scholar
• Nadal E, Gine E, Blade J, Esteve J, Rosinol L, Fernandez-Aviles F, et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004; 33: 61–64
   PubMed Web of Science ®Google Scholar
• O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731–737
   PubMed Web of Science ®Google Scholar
• Tribalto M, Amadori S, Cudillo L, Caravita T, Del Poeta G, Meloni G, et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica 2000; 85: 52–58
   PubMed Web of Science ®Google Scholar
• Alexanian R, Weber D, Giralt S, Dimopoulos M, Delasalle K, Smith T, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27: 1037–1043
   PubMed Web of Science ®Google Scholar
• Kyle R A, Leong T, Li S, Oken M M, Kay N E, Van Ness B, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006; 106: 1958–1966
   PubMed Web of Science ®Google Scholar
• Hussein M A, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006; 81: 889–895
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Desikan K R, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55–65
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology™ Multiple Myeloma (V.3.2007), Available at http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed on 5 Feb 2007
   Google Scholar
• De la Rubia J, Blade J, Lahuerta J J, Ribera J M, Martinez R, Alegre A, et al. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica 2006; 91: 621–627
   PubMed Web of Science ®Google Scholar
• Majolino I, Vignetti M, Meloni G, Vegna M L, Scime R, Tringali S, et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Haematologica 1999; 84: 844–852
   PubMed Web of Science ®Google Scholar
• Alegre A, Diaz-Mediavilla J, San-Miguel J, Martinez R, Garcia Larana J, Sureda A, et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant 1998; 21: 133–140
   PubMed Web of Science ®Google Scholar
• Kane R C, Farrell A T, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006; 12: 2955–2960
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498
   PubMed Web of Science ®Google Scholar
• Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmaver E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, in press
   Google Scholar
• Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson P G, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165–172
   PubMed Web of Science ®Google Scholar
• Richardson P G, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617
   PubMed Web of Science ®Google Scholar
• Richardson P G, Mitsiades C, Ghobrial I, Anderson K. Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol 2006; 18: 598–608
   PubMed Web of Science ®Google Scholar
• Boccadoro M, Palumbo A, Bringhen S, Merletti F, Ciccone G, Richiardi L, et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002; 87: 846–850
   PubMed Web of Science ®Google Scholar
• Clark R E, Brammer C G. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859–863
   PubMed Web of Science ®Google Scholar
• Gandhi M K, Jestice K, Scott M A, Bloxham D, Bass G, Marcus R E. The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9–13
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–744
   PubMed Web of Science ®Google Scholar
• Prince H M, Imrie K, Sutherland D R, Keating A, Meharchand J, Crump R M, et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996; 93: 142–145
   PubMed Web of Science ®Google Scholar
• Fitzgerald M, Fraser C, Webb I, Schenkein D, Esseltine D, Weich N S. Normal hematopoietic stem cell function in mice following treatment with bortezomib. Biol Blood Marrow Transplant 2003; 9: 121
   Google Scholar
• Lonial S, Waller E K, Richardson P G, Jagannath S, Orlowski R Z, Giver C R, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777–3784
   PubMed Web of Science ®Google Scholar
• Lonial S, Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmaver E, et al. Hematologic profiles in the phase 3 APEX trial. Blood 2005; 106: 970a
   Web of Science ®Google Scholar
• Abrahamsen J F, Wentzel-Larsen T, Bruserud O. Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2 × 10(6) CD34+ cells/kg. Cytotherapy 2004; 6: 356–362
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826–831
   PubMed Web of Science ®Google Scholar
• Venditti A, Battaglia A, Del Poeta G, Buccisano F, Maurillo L, Tamburini A, et al. Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods. Bone Marrow Transplant 1999; 24: 1019–1027
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106: 35–39
   PubMed Web of Science ®Google Scholar
• Bender J G, To L B, Williams S, Schwartzberg L S. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329–341
   PubMedGoogle Scholar
• Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–596
   PubMed Web of Science ®Google Scholar
• Allan D S, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, et al. Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 967–972
   PubMed Web of Science ®Google Scholar
• Morris C L, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, et al. Mobilization of CD34+ cells in elderly patients (>/=70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413–423
   PubMed Web of Science ®Google Scholar
• Desikan R, Barlogie B, Sawyer J, Ayers D, Tricot G, Badros A, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95: 4008–4010
   PubMed Web of Science ®Google Scholar
• Oakervee H E, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755–762
   PubMed Web of Science ®Google Scholar
• Jagannath S, Durie B GM, Wolf J L, Camacho E S, Irwin D, Lutzky J, et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Blood 2006; 108: 238a–239a
   PubMed Web of Science ®Google Scholar
• Harousseau J-L, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa A-M, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498–1505
   PubMed Web of Science ®Google Scholar
• Harousseau J-L, Marit G, Caillot D, Casassus P, Facon T, Mohty M, et al. VELCADE/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial. Blood 2006; 108: 21a
   Web of Science ®Google Scholar
• Rosiñol L, Oriol A, Mateos M, Sureda A, Diaz-Mediavilla J, Herrero C, et al. Final results of a phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen prior autologous stem cell transplantation (ASCT) in younger patients with multiple myeloma (MM): efficacy and clinical implications of tumor response. J Clin Oncol 2007; 25: 447s
   PubMed Web of Science ®Google Scholar
• Popat R, Oakervee H E, Curry N, Foot N, Morris C, Drake M, et al. Reduced dose PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2005; 106: 717a
   PubMed Web of Science ®Google Scholar
• Popat R, Oakervee H, Curry N, Odeh L, Foot N, Esseltine D-L, et al. Long-term follow-up of PAD for untreated multiple myeloma. Haematologica 2007; 92(Suppl 2)P0–725
   Google Scholar
• Gevorgyan A, Pitini V, Arrigo C, Altavilla G, Naro C, Alu M, et al. Level of circulating endothelial cells as new biomarker in patients with multiple myeloma, treated with bortezomib-pegylated liposomal doxorubicin-dexamethasone combination. J Clin Oncol 2006; 24: 684s
   Google Scholar
• Jakubowiak A J, Al-Zoubi A, Kendall T, Brozo C, Khaled Y, Mineishi S, et al. Combination therapy with bortezomib (VELCADE®), Doxil®, and dexamethasone (VDD) in newly diagnosed myeloma: Updated results of phase II clinical trial. Haematologica 2007; 92(Suppl 2)P0–721
   Google Scholar
• Orlowski R Z, Peterson B L, Sanford B, Chanan-Khan A A, Zehngebot L M, Watson P R, et al. Bortezomib and pegylated liposomal doxorubicin as induction therapy for adult patients with symptomatic multiple myeloma: Cancer and Leukemia Group B Study 10301. Blood 2006; 108: 239a
   Web of Science ®Google Scholar
• Di Carlo B A, Stern J L, Schuster M, Shore T, Harpel J, Pearse R, et al. Breaking the plateau response in myeloma: preliminary results of a phase II pilot study of sequential bortezomib in combination with dexamethasone and pegylated liposomal doxorubicin (DoVeD) in patients no longer responsive to standard induction regimens. Blood 2006; 108: 1006a
   Web of Science ®Google Scholar
• Stern J L, Di Carlo B, Schuster M W, Shore T B, Harpel J G, Pearse R, et al. Bortezomib added to the standard mobilization regimen of G-CSF and high-dose cyclophosphamide is a safe and effective combination for a high yield stem cell collection while promoting further tumor mass reduction in myeloma. Blood 2006; 108: 837a
   Web of Science ®Google Scholar
• Badros A, Goloubeva O, Fenton R, Rapoport A P, Akpek G, Harris C, et al. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 210–216
   PubMedGoogle Scholar
• Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176–185
   PubMed Web of Science ®Google Scholar
• Cottler-Fox M, Holley D, Whigham L, Stover J, Rasmussen E, Zangari M, et al. Hematopoietic progenitor cell (HPC) mobilization after initial therapy of multiple myeloma including Velcade: ability to collect HPC as a function of Velcade dosing. Blood 2004; 104: 788a
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, Bolejack V, Zangari M, van Rhee F, Shaughnessy J, et al. High CR and near-CR rate with bortezomib incorporated into up-front therapy of multiple myeloma with tandem transplants. J Clin Oncol 2006; 24: 426s
   Web of Science ®Google Scholar
• Uy G L, Fisher N M, Devine S M, Tomasson M H, DiPersio J F, Vij R. Bortezomib does not impair cytokine induced mobilization of stem cells prior to autologous transplantation in multiple myeloma. Blood 2005; 106: 821a
   Web of Science ®Google Scholar
• Rajkumar S V, Hayman S R, Lacy M Q, Dispenzieri A, Geyer S M, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Torjman L, Ben Romdhane N, Ladeb S, El Omri H, Ben Othman T, et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 2005; 36: 193–198
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K RA. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16–19
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy M Q, Hayman S R, Buadi F K, Gastineau D A, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, e-pub ahead of print
   Web of Science ®Google Scholar
• Mazumder A, Jagannath S, Vesole D. The effect of induction therapy with novel agents on stem cell mobilization in multiple myeloma. J Clin Oncol 2007; 25: 466s
   Web of Science ®Google Scholar
• Kumar S, Lacy M Q, Dispenzieri A, Rajkumar S V, Fonseca R, Geyer S, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004; 34: 485–490
   PubMed Web of Science ®Google Scholar
• Patriarca F, Damiani D, Fanin R, Grimaz S, Geromin A, Cerno M, et al. High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome. Haematologica 2000; 85: 269–274
   PubMed Web of Science ®Google Scholar
• Anderson K, Richardson P, Chanan-Khan A, Schlossman R, Munshi N, Oaklander A, et al. Single-agent bortezomib in previously untreated multiple myeloma: results of a phase II multicenter study. J Clin Oncol 2006; 24: 423s
   Web of Science ®Google Scholar
• Wang M, Giralt S, Delasalle K, Handy B, Alexanian R. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology 2007; 12: 235–239
   PubMed Web of Science ®Google Scholar
• Borrello I, Ferguson A, Huff C A, George S, Biedryzcki B, Cornblath D, et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma: efficacy and neurotoxicity. Blood 2006; 108: 1006a
   Web of Science ®Google Scholar
• Lokhorst H M, Sonneveld P, Cornelissen J J, Joosten P, van Marwijk K M, Meinema J, et al. Induction therapy with vin-cristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma. Bone Marrow Transplant 1999; 23: 317–322
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp P R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
   PubMed Web of Science ®Google Scholar
• Harousseau J-L, Jagannath S, Richardson P G, Sonneveld P, Schuster M W, Esseltine D L, et al. Bortezomib in combination with high-dose dexamethasone (HD dex) and erythropoietin (EPO) does not result in an increased risk of thromboembolic complications. Blood 2006; 108: 1011a
   Web of Science ®Google Scholar
• Richardson P G, Briemberg H, Jagannath S, Wen P Y, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113–3120
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Richardson P, Sonneveld P, Schuster M, Irwin D, Stadtmaver E, et al. Frequency, characteristics, and reversibility of peripheral neuropathy (PN) in the APEX trial. Blood 2005; 106: 111a
   Web of Science ®Google Scholar
• Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829
   PubMed Web of Science ®Google Scholar
• Knudsen L M, Nielsen B, Gimsing P, Geisler C. Autologous stem cell transplantation in multiple myeloma: outcome in patients with renal failure. Eur J Haematol 2005; 75: 27–33
   PubMed Web of Science ®Google Scholar
• San Miguel J F, Lahuerta J J, Garcia-Sanz R, Alegre A, Blade J, Martinez R, et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. Hematol J 2000; 1: 28–36
   PubMedGoogle Scholar
• Knudsen L M, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207–212
   PubMed Web of Science ®Google Scholar
• Knudsen L M, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181
   PubMed Web of Science ®Google Scholar
• Bladé J, Fernandez-Llama P, Bosch F, Montoliu J, Lens X M, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gertz M A, Witzig T E, Lust J A, Lacy M Q, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33
   PubMed Web of Science ®Google Scholar
• Sakhuja V, Jha V, Varma S, Joshi K, Gupta K L, Sud K, et al. Renal involvement in multiple myeloma: a 10-year study. Ren Fail 2000; 22: 465–477
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A A, Kaufman J L, Mehta J, Richardson P G, Miller K C, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007; 109: 2604–2646
   PubMed Web of Science ®Google Scholar
• Ludwig H L, Zojer N, Kuenburg E, Graf H. Reversal of acute multiple myeloma (MM)-induced renal failure by bortezomib-combination therapy. A report of three cases. Haematologica 2005; 90: 430
   Google Scholar
• Mohrbacher A, Levine A M. Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients. J Clin Oncol 2005; 23: 612s
   Web of Science ®Google Scholar
• Mulkerin D, Remick S, Ramanathan R, Hamilton A, Takimoto C, Davies P, et al. A dose-escalating and pharmacologic study of bortezomib in adult cancer patients with impaired renal function. J Clin Oncol 2006; 24: 87s
   Web of Science ®Google Scholar
• Nozza A, Siracusano L, Armando S. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function. Clin Ther 2006; 28: 953–959
   PubMed Web of Science ®Google Scholar
• Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007; 137: 429–435
   PubMed Web of Science ®Google Scholar
• Mateos M V, Hernandez J M, Hernandez M T, Gutierrez N C, Palomera L, Fuertes M, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study. Blood 2006; 108: 2165–2172
   PubMed Web of Science ®Google Scholar
• Fonseca R, Stewart A K. Targeted therapeutics for multiple myeloma: the arrival of a risk-stratified approach. Mol Cancer Ther 2007; 6: 802–810
   PubMed Web of Science ®Google Scholar